baber/WOPTO huggingface dataset:
Patent NZ-585901-A (NZ)
Title: System and method for compressing video based on detected intraframe motion
Inventor: VAN DER LAAN ROGER
IPC: H04N7/26
Filed: 2008-12-04
Abstract: A computer-implemented method for performing video compression comprises logically subdividing each of a sequence of images into a plurality of tiles, detecting motion within the sequence of images occurring at each of the positions of each of the tiles; and encoding each tile within each image of the sequence of images using a first compression format or a second compression format. Each of the tiles has a defined position within each of the sequence of images and the defined position remains the same between successive image. The frequency at which a particular tile is encoded according to the first compression format across the sequence of images is based on the detected amount of motion at the position of that tile across the sequence of images. The first compression format comprises intraframe coding and the second compression format comprises interframe coding.
Patent NZ-588041-A (NZ)
Title: Target amplification and sequencing with primers comprising triplex forming monomer units
Inventor: LISBY GORM
IPC: C12Q1/68
Filed: 2009-03-10
Abstract: Disclosed is a method for extension of a primer, the method comprising the steps of Providing a template nucleic acid Providing a first oligonucleotide primer Providing a polymerase Providing nucleotide triphosphates Mixing the components of steps a-d and providing conditions that allow the primer to anneal to the template wherein the first oligonucleotide is an oligonucleotide of a length between 5 and 60 nt. comprising a triplex forming monomer unit (TINA monomer) of the formula Z, wherein Z is described by the general structure: X  ,L   I1   C   I2 wherein X is a backbone monomer unit that can be incorporated into the backbone of a oligonucleotide or a oligonucleotide analogue, or PNA, or PNA analogues, L is a linker, I1 is a first intercalator comprising at least one essentially flat conjugated system, C is an optional conjugator and I2 is a second intercalator comprising at least one essentially flat conjugated system Under conditions allowing primer extension, extending the first oligonucleotide annealed to the template.
Patent NZ-588268-A (NZ)
Title: Adjustment of endotracheal tube cuff filling
Inventor: EFRATI SHAI
IPC: A61M16/04
Filed: 2006-08-21
Abstract: A patient intubating system includes an endotracheal tube to be inserted into the airway and which includes a cuff that can be inflated below the vocal cords and above the lungs. The system includes a measuring device for measuring at least one parameter that is indicative of leakage of secretion from above the cuff toward the lungs. The measured parameters may be acoustic, optical, pressure or flow parameters but do not include a measure of the carbon dioxide concentration between the cuff and the vocal cords which is a known measure for leakage detection in such intubating systems.
Patent NZ-589023-A (NZ)
Title: Non-chlorinated concentrated all-in-one acid detergent and method for using the same
Inventor: AHMED FAHIM U
IPC: C11D7/26
Filed: 2005-08-08
Abstract: Disclosed is a liquid detergent use solution composition comprising: an acid selected from the group consisting of inorganic acids (such as a mineral acid selected from the group consisting of phosphoric, nitric, hydrochloric, sulfuric, and sulfamic acids and mixtures thereof), organic acids (preferably selected from a group consisting of citric acid, methane sulfonic acid, ethanesulfonic acid, propanesulfonic acid, butanesulfonic acid, acetic acid, hydroxyacetic acid, propionic acid, hydroxypropionic acid, alpha-ketopropionic acid, butyric acid, mandelic acid, valeric acid, succinic acid, tartaric acid, malic acid, oxalic acid, fumaric acid, adipic acid, maleic acid, sorbic acid, benzoic acid, succinic acid, glutaric acid, adipic acid, alpha-hydroxy acids, ethylenediaminetetraacetic acid (EDTA), phosphonic acid, octyl phosphonic acid, acrylic acid, polyacrylic acid, aspartic acid, polyaspartic acid, p-hydroxybenzoic acids, iminoacetic acids, and mixtures thereof), and mixtures thereof; and from about 0.00003-0.0075% by weight of a fatty alkyl-1,3-diaminopropane or salt thereof having the general formula R-NH-CH2CH2CH2NH2, wherein R is a C4-C22 alky I group; said composition having a pH of between 0.1-5.
Patent NZ-589450-A (NZ)
Title: Method for producing chiral 8-(3-amino-piperidin-1-yl)-xanthines and intermediates thereof
Inventor: PFRENGLE WALDEMAR
IPC: A61K31/522
Filed: 2005-11-02
Abstract: The disclosure relates to phthalimido-piperidine derivatives of the general formula (II), wherein the variables are as defined in the specification. The disclosure also provides a process for preparing optically active 3-(phthalimido)piperidine. These compounds are used to further synthesise 8-(3-aminopiperidin-1-yl)xanthine that are suitable for treating diabetes mellitus type I or type II, prediabetes or impaired glucose tolerance, arthritis, obesity, allograft transplantation or osteoporosis caused by calcitonin.
Patent NZ-589488-A (NZ)
Title: Assay device for determining and indicating time since conception by comparing a measured hCG level to two stored threshold levels
Inventor: ELLIS JAYNE
IPC: G01N33/543
Filed: 2009-06-03
Abstract: 589488 Disclosed is an assay result reader when used with an assay or assay device (50) adapted to calculate a quantitative estimate of the length of time since conception in a female human subject. The assay result reader is comprised of: a) a first stored analyte threshold corresponding to 14 days since conception; b) a second stored analyte threshold corresponding to 21 days since conception; c) a stored minimum pregnancy threshold (PTDmin); d) a measurement means adapted to measure an analyte signal value; and e) a display means (53) adapted to display a time since conception. The analyte signal value measured by the measurement means corresponds to the level of hCG in a urine sample obtained from the subject. The measurement means is also adapted to compare the analyte signal value to the minimum pregnancy threshold and the first and second stored analyte thresholds. The measurement means provides a quantitative estimate of the length of time since conception based upon this comparison. The time since conception is defined relative to the date of LH surge. The results displayed by the reader are as follows: "not pregnant" if the analyte signal is less than the minimum pregnancy threshold; 1-2 weeks if the analyte signal is less than the first analyte threshold but greater than the minimum pregnancy threshold; 2-3 weeks if the analyte signal is greater than or equal to the first threshold but less than or equal to the second threshold; and 3+ weeks if the analyte signal is greater than the second threshold.
Patent NZ-590255-A (NZ)
Title: Combinations of tralopyril and copper biocides
Inventor: KEMPEN TONY MATHILDE JOZEF
IPC: A01N43/36
Filed: 2007-01-31
Abstract: Disclosed is a composition comprising a combination of 4-bromo-2-(4-chlorophenyl)-5- (trifluoromethyl)-1H-pyrrole-3-carbonitrile (tralopyril), or a salt thereof, as component (I), and as a component (II) a copper compound selected from Cu2O, Cu(OH)2, copper pyrithione, CuSCN, CuCO3; whereby component (I) and one of the components (II) are in respective proportions to provide a synergistic effect against fouling organisms.
Patent NZ-592856-A (NZ)
Title: Antibodies against human angiopoietin 2
Inventor: BRINKMANN ULRICH
IPC: A61K39/395
Filed: 2009-12-14
Abstract: Disclosed is an antibody specifically binding to human angiopoietin-2 (ANG-2), wherein: a) the heavy chain variable domain comprises a CDR3 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO: 2, and a CDR1 region of SEQ ID NO: 3, and b) the light chain variable domain comprises a CDR3 region of SEQ ID NO: 4, a CDR2 region of SEQ ID NO: 5, and a CDR1 region of SEQ ID NO: 6.
Patent NZ-593657-A (NZ)
Title: Enema preparations and their use
Inventor: GODAL ASLAK
IPC: A61K9/00
Filed: 2009-12-23
Abstract: ABSTRACT - 593657 The disclosure relates to a liquid enema preparation suitable for administration intra-colonically which comprises a photosensitiser which is a 5-aminolevulinic acid (5-ALA) ester, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient and which further comprises: (a) one or more viscosity enhancing agents; and optionally one or more of the following: (b) one or more mucoadhesive agents or one or more mucolytic agents; (c) one or more penetration enhancers; and (d) one or more chelating agents; wherein the viscosity of the preparation increases after instillation into the area of interest. This enema preparation is suitable for the photodynamic treatment or diagnosis of cancer or non-cancerous conditions in the lower part of the gastrointestinal tract selected from inflammatory bowel disease, ulcerative colitis, Crohn's disease and irritable bowel syndrome
Patent NZ-594088-A (NZ)
Title: Wearable fishing rod holder
Inventor: SMITH WAYNE TRACY
IPC: A01K97/10
Filed: 2011-07-15
Abstract: Disclosed is a fishing rod holder for securing a fishing rod on a person. The holder includes a fishing rod retention means which has a single rod receiver for receiving and holding the fishing rod. The rod receiver is constructed of a deformable resilient cushioned material. The rod receiver is retained from a single section of the rod above the rod handle. The rod receiver includes means that orientates the receiver and rod in a generally vertical position during operating conditions. The fishing rod retention means includes a support means to secure the rod retention means to a person.
Patent NZ-595767-A (NZ)
Title: Composition for the treatment of prostate cancer
Inventor: OLESEN TINE KOLD
IPC: A61K9/00
Filed: 2010-04-30
Abstract: Provided is the use of degarelix or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of prostate cancer, wherein the medicament comprises a Iyophilisate of degarelix and an excipient dissolved in a solvent, and is administered to a patient at a starting dose of between 200 and 300 mg of degarelix at a concentration of between 20 and 80 mg of degarelix per mL solvent; followed 14- 56 days after the starting dose by a maintenance dose of between 320 and 550 mg of degarelix at a concentration of between 50 and 80 mg degarelix per mL solvent; optionally followed by one or more further maintenance doses of between 320 and 550 mg of degarelix at a concentration of between 50 and 80 mg dega'relix per mL solvent administered with an interval of 56 days to 112 days between each maintenance dose.
Patent NZ-597848-A (NZ)
Title: Improved apparatus for carrying data storage carriers
Inventor: SAMUEL JANENE ELLEN
IPC: A45F5/00
Filed: 2010-06-09
Abstract: An apparatus (10) when used in carrying one or more data storage carriers (12) for safe keeping and protecting against loss includes a lanyard (14) adapted to be worn around a body part of a person, such as the wrist or the neck. A split ring (18) is connected to the lanyard (14), and a desired number of tags (20) are connected to the split ring (18). Each tag (20) has an adhesive surface on one side for attaching a respective carrier thereto. The tag also has a hole (22) through which the split ring (18) passes to thereby connect the carrier (12) to the split ring (18).A split ring (18) is connected to the lanyard (14), and a desired number of tags (20) are connected to the split ring (18). Each tag (20) has an adhesive surface on one side for attaching a respective carrier thereto. The tag also has a hole (22) through which the split ring (18) passes to thereby connect the carrier (12) to the split ring (18).
Patent NZ-600130-A (NZ)
Title: A milking implement
Inventor: VAN DEN BERG KAREL
IPC: A01J5/003
Filed: 2007-08-15
Abstract: 600130 A milking implement is disclosed which includes a frame (10), a sub-frame (20), at least one teat cup holder (26), a replacing means, and a milk line (32). The sub-frame (20) is connected with the frame (10) and is adjustable in height. The teat cup holder (26) has a teat cup (28) movable relative thereto, fastened to the bottom of the sub-frame (20), and the replacing means is connected with the teat cup (28). The milk line (32) comprises a flexible hose having a first end connected with the teat cup (28), where the teat cup holder (26) is tiltable over an angle 'a' in a tilting plane relative to the sub-frame (20), and the hose extends substantially in the tilting plane near the first end.
Patent NZ-600584-A (NZ)
Title: Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
Inventor: MASTERNAK KRZYSZTOF
IPC: A61K39/395
Filed: 2009-05-05
Abstract: 600584 Disclosed is an isolated nucleic acid encoding fully human monoclonal antibodies that recognize IL- 17F, the IL- 17F homodimer, IL- 17A, the IL- 17A homodimer, and/or the heterodimeric IL- 17A/IL-17F protein complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
Patent NZ-602673-A (NZ)
Title: Medical devices including medicaments and methods of making and using same
Inventor: DOSHI PRAFUL
IPC: A61K9/00
Filed: 2011-04-02
Abstract: The present disclosure recognizes that medical devices, such as but not limited to contact lenses, can be made having a coating made at least in part using printing technologies to provide drug storage and drug release structures. The coating preferably includes at least one drug reservoir layer and a least one barrier layer, and can include structures, such as but not limited to capillary structures, that alone or in combination modulate the release of the drug from the coating. One aspect of the present dislcosure is a medical device that incorporates a drug in at least one coating. A second aspect is a method of making a medical device that incorporates a drug in at least one coating. A third aspect is a method of using a medical device of the present invention to treat or prevent a disease, disorder or condition.
Patent NZ-603065-A (NZ)
Title: Method for using a bacillus subtilis strain for prophylaxis and treatment of gastro-intestinal conditions
Inventor: SCHMIDT JOSEPH EARL
IPC: A61P1/12
Filed: 2011-03-17
Abstract: Disclosed is the use of Bacillus subtilis QST713 (NRRL Accession Number B21661) or a mutant of Bacillus subtilis QST713 for the manufacture of a medicament for the treatment or prevention of a gastro-intestinal disorder in a human, wherein the gastro-intestinal disorder is selected from the group consisting of acute diarrhoea, Clostridium dificile-associated infection, inflammatory bowel disease, irritable bowel disorder, and antibiotic-associated diarrhoea and wherein the mutant Bacillus subtilis QST713 has sequence identity to the Bacillus subtilis QST713 of at least 98%.
Patent NZ-603082-A (NZ)
Title: Strap with improved column stiffness
Inventor: VAN ERDEN DONALD L
IPC: B65D63/10
Filed: 2011-04-22
Abstract: 603082 A strap (10) having increased column stiffness is disclosed. The strap includes a leading edge (20) and a trailing edge forming a length of the strap, a first outer edge and second outer edge defining a width of the strap, and a first side and a second side defining a thickness of the strap. A crush region (18) is formed in the first or second side, between and generally parallel to the first and second outer edges. The crush region is defined by a thickness that is less than the thickness of the strap adjacent to the crush region. The crush region forms a line along which a bend may be formed in the strap. The bend increases the column stiffness of the strap at least about 67% over that of a comparable flat strap. The bend defines an acute angle (24) and an obtuse angle in the strap as viewed in cross-section.
Patent NZ-608708-A (NZ)
Title: Novel gpr 119 agonists
Inventor: PINGALI HARIKISHORE
IPC: C07D417/14
Filed: 2011-10-05
Abstract: Provided are pyrimidine-dioxothiazolidine/dioxooxazolidine derivative compounds of the general formula (I), wherein the variables are as defined in the specification. Examples of the compounds include (Z)-tert-Butyl 4-((6-(4-((2,4-dioxothiazolidin-5-ylidene)methyl)phenoxy)-5-methylpyrimidin-4-yl)oxy)piperidine-1-carboxylate and (Z)-5-(3-((6-((1-(5-bromopyridin-2-yl)piperidin-4-yl)oxy)pyrimidin-4-yl)oxy)benzylidene)thiazolidine-2,4-dione. The compounds are GPR 119 agonists. The compounds may be useful in the treatment of obesity, diabetes and related metabolic disorders.
Patent NZ-610761-A (NZ)
Title: Concentrated flavour base product
Inventor: LIAN HWEE PENG REBECCA
IPC: A23L27/21
Filed: 2011-12-12
Abstract: Disclosed is a method for preparing a culinary flavouring product from ingredients including a tonality delivering ingredient and other ingredients, comprising the steps of: a) thermally reacting the tonality delivering ingredient with at least one thermal reaction precursor to obtain an intermediate product; and b) processing the intermediate product of step a) with the other ingredients to obtain the final culinary flavouring product, wherein the other ingredients are selected from the group consisting of MSG, salt, water, and a combination thereof; wherein step b) comprises granulation, drying, pasteurisation, or a combination thereof; and wherein the tonality delivering ingredient is selected from edible meat, aromatic plants, vegetables, or a combination thereof; and wherein the thermal reaction precursor comprises a carbonyl-containing compound selected from the group consisting of mono- and disaccharides, sugar derivatives, sources of sugar and/or sugar derivatives and their hydrolysates, glucose syrup, fructose syrup, xylose syrup, and hydrolysed pectins.
Patent NZ-631007-A (NZ)
Title: Anti-c5 antibodies having improved pharmacokinetics
Inventor: TAMBURINI PAUL P
IPC: C07K16/36
Filed: 2014-09-11
Abstract: Disclosed is an isolated antibody, or antigen-binding fragment thereof, that: (a) binds to complement component human C5; (b) inhibits the cleavage of C5 into fragments C5a and C5b; and (c) comprises: (i) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO: 23, (ii) a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO: 19, (iii) a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO: 3, (iv) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO: 4, (v) a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO: 5, and (vi) a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO: 6, wherein the sequences are as defined in the complete specification. Further disclosed is the use of said antibody in the manufacture of a medicament for the treatment of a patient afflicted with a C5 mediated complement-associated condition.
Patent NZ-703771-A (NZ)
Title: Milking equipment
Inventor: DUKE JAMES RICHARD JOHN
IPC: A01J7/04
Filed: 2013-07-24
Abstract: The invention is in the field of milking equipment and, more particularly, to a milking cluster of teat cups and a distributor device for mounting with the cluster and for distributing treatment fluid to the teat cups of the cluster, post milking. The invention relates to a distributor device for distributing treatment fluid to teat cups of a milking cluster. The problem addressed by the invention is that a malfunction could cause treatment fluid to be sent to the distributor and therefore to the teat cups during milking, contaminating the milk. The solution proposed by the invention is to provide a safety valve in the distributor that vents the inlet of the distributor to external environment during milking, so that any treatment fluid that is wrongly sent to the distributor during milking will exit through the vent, rather than being sent to the teat cups.
Patent NZ-712805-A (NZ)
Title: Device for closing beverage containers and assembly of such a device and a beverage container
Inventor: VAN DEN BROEK LUCAS
IPC: B65D81/32
Filed: 2014-03-11
Abstract: Device (3) for closing beverage containers, comprising a basic structure (8) configured for coupling to the beverage container (2), the basic structure enclosing at least one passage channel for beverage, a closing element (10) coupled releasably to the basic structure for closing the at least one passage channel, at least one axially displaceable holder (14) which is arranged at least partially in the passage channel and which is at least partially filled with an additive to be added to the beverage at least one lower perforation structure (16) positioned under an underside of the holder remote from the closing element and configured to perforate the underside of the holder during downward displacement of the holder in the passage channel in the direction of the lower perforation structure, whereby the additive can be released to beverage present in the beverage container, wherein an openable upper side of the holder facing toward the closing element and an underside of the holder remote from the closing element initially close the holder substantially medium-tightly. Known devices have multiple components such as cover members requiring multiple steps to use the device. Additionally, the devices might prevent liquid from flowing out of the device, with liquid flowing along the water side of the device. In the present device, the upper face is openable, enabling it to be used as a beverage passage.
Patent NZ-715098-A (NZ)
Title: Apparatus for controlling fluid flow
Inventor: KAMEN DEAN
IPC: A61M5/168
Filed: 2012-12-21
Abstract: An apparatus (1), system and method for monitoring fluid flow in an intravenous drip are disclosed. The apparatus holds a drip chamber (4) in relation to an imaging device or processor (11, 19, 18, 20). Distortion of a background image or pattern due to refraction of light through the flowing, dripping liquid is detected by the processor. The estimated flow rate into the drip chamber (4) is then used to generate an error signal to control a valve actuator (6) with a closed loop control system (14).
Patent NZ-730702-A (NZ)
Title: N-(hetero)aryl-substituted heterocyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system
Inventor: CREMONESI SUSANNA
IPC: C07D401/14
Filed: 2015-09-14
Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R9a, R9b, R9c, R9d, R9e, R9f, m, n, A, L and B are as defined herein.
Patent NZ-736649-A (NZ)
Title: Grid mesh anchor
Inventor: LINTON STEPHEN
IPC: E04G21/32
Filed: 2016-06-16
Abstract: The present invention relates to an anchor assembly (10) at a grid mesh platform (12) for providing a secure point of attachment and overcomes the problem of the anchorage being misplaced, being a tripping hazard for workers above the grid mesh and or lacking adequate support to distribute the weight safely. The anchor assembly (10) comprises a housing in the form of an elongated case (14) with a central hollow channel (30), generally rectangular in shape with a flat base (16) and roof (18). The base (16) is provided with openings in the form of access slots (34) to provide access from the channel (30) to the exterior of the base (16). The anchor assembly (10) also comprises a suspension member (38) located within the channel (30). In operation the anchor assembly (10) spans adjacent structural members (24) underlying the mesh grid (12). A coupling member in the form of a sling (40) having an end loop is engaged by the suspension member (38) which passes through the end loop of the sling (40). The sling (40) also passes through one of the slots (34) in the base (16) of the elongated case (14). An opposite end of the sling (40) provides an anchor point, typically for a worker wearing a harness.